PDCD1 and lung carcinoma: In addition, corresponding validation was also performed for different histological types of NSCLC and chemotherapy combined with different PD1 drug groups, and there was no difference between the histological types of lung cancer and different PD-1 antibodies in predicting the efficacy of this biomarker.